|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5360 EUR | -3.94% |
|
-13.27% | -65.10% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 10/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Company Valuation: AB Science
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 332.2 | 180.9 | 57.55 | 112 | 44.65 | - | - |
| Change | - | -45.55% | -68.19% | 94.7% | -60.15% | - | - |
| Enterprise Value (EV) | 332.2 | 180.9 | 57.55 | 112 | 44.65 | 44.65 | 44.65 |
| Change | - | -45.55% | -68.19% | 94.7% | -60.15% | 0% | 0% |
| P/E | -24.4x | -17.8x | -5.88x | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0.6x | 0.2x | - | - | - | - |
| Capitalization / Revenue | - | 187x | 53.7x | 95.4x | 37.2x | 34.3x | 27.9x |
| EV / Revenue | - | 0x | 0x | 0x | 37.2x | 34.3x | 27.9x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | 0x | -6.87x | -6.98x | - |
| EV / FCF | - | -0x | - | -0x | -6.98x | -12.4x | -11.4x |
| FCF Yield | - | -9.52% | - | -4.08% | -14.3% | -8.06% | -8.73% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.29 | -0.2 | -0.15 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 | 1.6 |
| EBITDA | - | -11.16 | -5.416 | - | - | - | - |
| EBIT 1 | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 | - |
| Net income | -13.62 | -10.05 | -7.831 | - | - | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 7.0900 | 3.5550 | 0.8820 | 1.5360 | 0.5580 | 0.5580 | 0.5580 |
| Nbr of stocks (in thousands) | 46,861 | 50,891 | 65,248 | 72,947 | 80,015 | - | - |
| Announcement Date | 01/03/23 | 15/05/24 | 13/05/25 | 13/05/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 5.1Cr | |
| 64.89x | 5.24x | 19.49x | 2.66% | 31TCr | |
| 23.22x | 3.19x | 11.32x | 1.71% | 6.79TCr | |
| 11.66x | 5.97x | 9.09x | - | 923.05Cr | |
| 17.01x | 2.16x | 7.41x | 2.62% | 843.12Cr | |
| 20.49x | 5.78x | 16.35x | -.--% | 407.28Cr | |
| 32.47x | 6.16x | 17.62x | - | 377.19Cr | |
| 38.55x | 2.21x | 27.68x | 0.79% | 354.49Cr | |
| 105.48x | - | - | -.--% | 272.44Cr | |
| Average | 39.22x | 4.39x | 15.56x | 1.3% | 4.61TCr | |
| Weighted average by Cap. | 55.21x | 4.84x | 17.68x | 2.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AB Stock
- Valuation AB Science
Select your edition
All financial news and data tailored to specific country editions
